Inaktiver Wert

Idenix Pharmaceuticals Inc Aktie

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

AbbVie : Merck says hepatitis C drugs to lose breakthrough status	04.02.15
Idenix Pharmaceuticals : Merck dépasse les attentes malgré la concurrence des génériques	29.07.14
Apple : Wall St. edges up, lifted by mergers, acquisitions	10.06.14
Idenix Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Idenix Pharmaceuticals Inc.	10.06.14
Apple : U.S. futures dip, S&P 500 comes off fourth straight record	10.06.14

Manager	Titel	Alter	Seit
Teresa Dahlman IRC	Investor Relations Contact	-	-
Michele Liuzzi PRN	Corporate Officer/Principal	-	-
Adel Moussa PRN	Corporate Officer/Principal	-	01.03.02

Sektor

	% 1. Jan.	Kap.
CSL LIMITED	-4,78 %	86,13 Mrd.
SAMSUNG BIOLOGICS CO.,LTD.	+1,32 %	39,82 Mrd.
BIOGEN INC.	-19,27 %	30,42 Mrd.
UCB	+57,86 %	25,23 Mrd.
BIOMARIN PHARMACEUTICAL INC.	-16,09 %	15,36 Mrd.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14 %	11,95 Mrd.
INCYTE CORPORATION	-17,69 %	11,6 Mrd.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00 %	11,51 Mrd.
SWEDISH ORPHAN BIOVITRUM AB	+5,24 %	8,71 Mrd.